Claim 1 -- Unchanged by this Amendment; Previously Amended

--1. An antibody comprising at least one antibody-antigen binding site, said antibody exhibiting specific binding to human complement component C5, said specific binding being targeted to the alpha chain of human complement component C5, wherein the antibody 1) inhibits complement activation in a human body fluid, 2) inhibits the binding of purified human complement component C5 to either human complement component C3 or human complement component C4, and 3) does not specifically bind to the human complement activation product free C5a.--

Claim 2 -- Unchanged by This Amendment; Previously Amended

--2. The antibody of Claim 1 wherein the inhibition of complement activation in the human body fluid is measurable as an increment of blockade of C5a generation and an increment of blockade of complement hemolytic activity in the body fluid, said increment of blockade of C5a generation being substantially equal to said increment of blockade of complement hemolytic activity.--

Claim 3 -- Unchanged by this Amendment; Previously Amended

--3. The antibody of Claim 1 wherein, upon binding to human C5, there is a 60% to 90% reduction in the ability of C5 to bind to human complement component C3.--

Claim 4 -- Unchanged by this Amendment; Previously Amended

--4. The antibody of Claim 1 wherein, upon binding to human C5, there is a 60% to 90% reduction in the ability of C5 to bind to human complement component C4.--

Claim 5 -- Unchanged by this Amendment

--5. The antibody of Claim 1 wherein the antibody binds specifically to an isolated oligopeptide comprising an amino acid sequence corresponding to amino acid 8 through amino acid 12 of SEQ ID NO:1.--

K

Claim 6 -- Unchanged by this Amendment

--6. The antibody of Claim 1 wherein the inhibition of complement activation in the human body fluid is measurable as a substantially complete blockade of C5a generation in the body fluid and a substantially complete blockade of complement hemolytic activity in the body fluid when the antibody is added to the body fluid at a concentration yielding a ratio equal to or less than 10 moles of antibody-antigen binding sites of the antibody to 1 mole of human C5 in the body fluid.--

Claim 7 -- Unchanged by this Amendment

--7. The antibody of Claim 1 wherein the antibody is a humanized antibody.--

Claim 8 -- Unchanged by this Amendment

--8. The antibody of Claim 1 wherein the antibody is an scFv.--

Claim 9 -- Unchanged by this Amendment

--9. A nucleic acid molecule comprising a nucleotide sequence encoding the antibody of Claim 1.--

Claim 10 -- Unchanged by this Amendment

--10. A nucleic acid vector comprising a first nucleic acid molecule covalently and operatively linked to a second nucleic acid molecule so that a host containing the vector expresses the polypeptide coded for by the first nucleic acid molecule, wherein the first nucleic acid molecule is the nucleic acid molecule of Claim 9.--

Claim 11 -- Unchanged by this Amendment

--11. A recombinant host cell containing the nucleic acid vector of Claim 10.--

Claim 12 -- Unchanged by this Amendment

--12. A method for producing an isolated C5 antibody polypeptide comprising growing the recombinant host cell of Claim 11 such that the

polypeptide encoded by the nucleotide sequence is expressed by the host cell, and isolating the expressed polypeptide, wherein the expressed polypeptide is an anti-C5 antibody.--

Claim 18 -- Unchanged by this Amendment

--18. The antibody of Claim 1, wherein, when administered to a human patient via intravenous infusion, the antibody provides complete complement inhibition at dosages below 0.005g/kg.--

Claim 19 -- Unchanged by this Amendment

--19. The antibody of Claim 1, wherein, when administered to a human patient via intravenous infusion, the antibody provides therapeutic benefits at dosages below 0.0022g/kg.--

Claim 20 -- Unchanged by this Amendment; Previously Amended

--20. The antibody of Claim 19, wherein the antibody is administered in association with an extracorporeal circulation procedure.--

Claim 21 -- Amended by this Amendment

--~~21~~. (twice amended) A sterile non-pyrogenic therapeutic agent comprising the antibody of Claim 1 in a formulation suitable for administration to a human. [and a pharmaceutically effective carrier.]--

Claim 22 -- Unchanged by this Amendment

--22. The therapeutic agent of Claim 21 wherein the antibody is a humanized immunoglobulin.--

Claim 23 -- Unchanged by this Amendment

--23. The therapeutic agent of Claim 21 wherein the antibody is an scFv.--

Claim 25 -- Unchanged by this Amendment; Previously Amended

--25. The therapeutic agent of Claim 21 wherein the antibody is made up of two or more heterodimeric subunits each containing one heavy and one light chain.--

Claim 26 -- Unchanged by this Amendment

--26. Antibody 5G1.1 scFv CB (humanized) having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:8.--

Claim 27 -- Unchanged by this Amendment

--27. An isolated antigen binding protein comprising:

1) a variable light region CDR1 comprising an amino acid sequence corresponding to amino acid residues 26-36 of SEQ ID NO:8,

2) a variable light region CDR2 comprising an amino acid sequence corresponding to amino acid residues 52-58 of SEQ ID NO:8,

3) a variable light region CDR3 comprising an amino acid sequence corresponding to amino acid residues 91 through amino acid 99 of SEQ ID NO:8,

4) a variable heavy region CDR1 comprising an amino acid sequence corresponding to amino acid residues 152 through amino acid 161 of SEQ ID NO:8,

5) a variable heavy region CDR2 comprising an amino acid sequence corresponding to amino acid residues 176 through amino acid 186 of SEQ ID NO:8,

6) a variable heavy region CDR3 comprising an amino acid sequence corresponding to amino acid residues 225 through amino acid 237 of SEQ ID NO:8,

said protein exhibiting specific binding to human complement component C5, said specific binding being targeted to the alpha chain of human complement component C5, wherein the protein inhibits complement activation in a human body fluid and does not specifically bind to the human complement activation product free C5a.--

K